FDA Advisory Committee Disclosures Sought In Public Citizen Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Unredacted curricula vitae could disclose privately funded grants, pending clinical trials, and pending publications among other information.
You may also be interested in...
Advisory Committees: FDA Gets Out Of The Redaction Business
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
Advisory Committees: US FDA Gets Out Of The Redaction Business
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.